Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending March 13, 2007. The report serves as a notification of transactions involving directors and persons discharging managerial responsibility, specifically regarding the US Retirement Savings Plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on a specific transaction event rather than general financial performance.
Material Changes
The material change reported is an increase in the notional allocation of Ordinary Share ADRs within the US Retirement Savings Plan following a re-valuation of the cash element. This transaction occurred on March 9, 2007, at a price of $55.59 per share.
Guidance, Outlook, and Risks
The filing contains no management commentary, guidance, outlook, or discussion of risks and contingencies. It is a compliance notification under Disclosure Rules 3.1.4R(1)(a) and 3.1.4R(1)(b).
Important Facts for Investors
- Transaction Date: March 9, 2007.
- Transaction Price: $55.59 per Ordinary Share ADR.
- Participants: Dr M M Slaoui, Mrs C Bruck Slaoui, Dr R G Greig, Mr W Louv, Dr D Pulman, Mr D Stout, and Mr C Viehbacher.
- Nature of Event: Increase in notional allocation of shares within the US Retirement Savings Plan.